Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Tianjin Medical University Cancer Institute & Hospital

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Radiotherapy Followed by Tiselizumab Combined With RCHOP in Previously Untreated Bulky Follicular Lymphoma

Phase 2

Recruiting

Conditions: Follicular Lymphoma

Interventions: Radiation: radiation therapy
Drug: Tiselizumab
Drug: Rituximab
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Vincristine
Drug: Prednisone

First Posted Date: 2024-11-26

Last Posted Date: 2024-11-26

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 20

Registration Number: NCT06704555

Locations: 🇨🇳
Tianjin Cancer Hospital, Tianjin, Tianjin, China

The Effect of Serum Ferritin in irAE

Not Applicable

Recruiting

Conditions: Immune-related Adverse Event
Malignant Solid Tumors
Acute Leukemia
Serum Ferritin

Interventions: Drug: PD-1 and PD-L1 inhibitor
Drug: Targeted drugs
Drug: chemotherapy drugs

First Posted Date: 2024-11-25

Last Posted Date: 2024-11-25

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 1500

Registration Number: NCT06702566

Locations: 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China

Cerebrospinal Fluid Immune Microenvironment Mechanism in Anaplastic Lymphoma Kinase Positive Lung Cancer Patients

Phase 2

Not yet recruiting

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Iruplinalib

First Posted Date: 2024-11-20

Last Posted Date: 2024-11-20

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 12

Registration Number: NCT06697990

Endoscopic Retrograde Cholangiopancreatography With Radiofrequency Ablation (ERCP-RFA) Combined With Envafolimab and Surufatinib Sequential Therapy for Unresectable Biliary Tract Carcinoma

Phase 2

Not yet recruiting

Conditions: Unresectable Biliary Tract Carcinoma

Interventions: Drug: Envafolimab and Surufatinib

First Posted Date: 2024-10-24

Last Posted Date: 2024-10-24

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 30

Registration Number: NCT06656559

Validate the Safety and Feasibility of the CT-guided Interventional Robot in Percutaneous Lung Cryablation Procedures

Not Applicable

Not yet recruiting

Conditions: Lung Cancer
Thoracic Cancer

Interventions: Procedure: CT-fluoroscopy guided master-slave intervetional robot-assisted lung Cryoablation

First Posted Date: 2024-09-03

Last Posted Date: 2024-09-03

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 20

Registration Number: NCT06581107

Locations: 🇨🇳
Tianjin Medical University, Cancer Institute & Hospital, Tianjin, Tianjin, China

Glofitamab Combination With Chidamide in Patients With Recurrent/Refractory DLBCL

Phase 2

Recruiting

Conditions: Diffuse Large B-Cell Lymphoma-Refractory
Diffuse Large B-Cell Lymphoma-Recurrent

Interventions: Drug: Glofitamab
Drug: Chidamide

First Posted Date: 2024-08-26

Last Posted Date: 2025-03-13

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 22

Registration Number: NCT06570447

Locations: 🇨🇳
Tianjin Medical University Cancer Insititute & Hospital, Tianjin, Tianjin, China

Disitamab Vedotin Combined With Tislelizumab and Capecitabine in the Perioperative Treatment of Locally Advanced Gastric Cancer With HER2 Overexpression

Phase 2

Recruiting

Conditions: Gastroesophageal Junction Adenocarcinoma
Gastric Cancer

Interventions: Drug: combination with Disitamab Vedotin and with Tislelizumab and Capecitabine

First Posted Date: 2024-08-19

Last Posted Date: 2024-08-19

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 40

Registration Number: NCT06560528

Locations: 🇨🇳
Tianjin Medical University Cancer Institute & Hospital, Tianjin, Tianjin, China
🇨🇳
Xuewei Ding, Tianjin, Tianjin, China

Donafenib Combine With Sintilimab and HAIC in Neoadjuvant of Resectable Hepatocellular Carcinoma

Phase 2

Not yet recruiting

Conditions: Hepatocellular Carcinoma

Interventions: Drug: Donafenib
Drug: Sintilimab
Other: HAIC

First Posted Date: 2024-07-22

Last Posted Date: 2024-07-22

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 30

Registration Number: NCT06512467

A Phase II Trial of Perioperative Adebrelimab Combined With XELOX in Resectable Locally Advanced Gastric/Gastroesophageal Junction Cancer (GC/GEJC)

Phase 2

Recruiting

Conditions: Adebrelimab (SHR-1316)
XELOX
GC/GEJC

Interventions: Drug: Adebrelimab
Drug: XELOX

First Posted Date: 2024-07-17

Last Posted Date: 2024-07-17

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 25

Registration Number: NCT06506292

Locations: 🇨🇳
Tianjin Cancer Institute and Hospital, Tianjin, Tianjin, China

Eliminating Breast Surgery for Breast Cancer Patients With Clinical Complete Response to Neoadjuvant Systemic Therapy

Phase 2

Not yet recruiting

Conditions: Breast Cancer

Interventions: Radiation: Neoadjuvant Chemotherapy combined with Neoadjuvant Radiotherapy

First Posted Date: 2024-07-12

Last Posted Date: 2024-07-12

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 200

Registration Number: NCT06498154

Locations: 🇨🇳
Tianjin medical university cancer institute and hospital, Tianjin, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy